Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 415-422

  Subraja, K ^a   Dkhar, S A ^a   Priyadharsini, R ^a   Ravindra, B K ^a   Shewade, D G ^a   Satheesh, S ^a   Sridhar, M G ^a   Narayan, S K ^a   Adithan, C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Clopidogrel; CYP2C19 polymorphism; Ischemic heart disease; Pharmacogenomics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 2C19 GENE; DRUG METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIA; ISCHEMIC HEART DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE AGGREGATION;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDIA; INDIVIDUALIZED MEDICINE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84877126753     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1381-8     Document Type: Article

References (24)

1. Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45:1157-1164
2. Giusti B (2010) Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics Personalized Med 3:33-50
3. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF (2011) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11:199-206
4. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247
5. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
6. Simon T, Verstuyft C, Krause MM, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375
7. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-518
8. Anichavezhi D, Chakradhara Rao US, Shewade DG, Krishnamoorthy R, Adithan C (2012) Distribution of CYP2C19*17 allele and genotypes in an Indian population. J Clin Pharm Ther 37(3):313-318
9. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot J-S, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830
10. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR (2011) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:328-332
11. Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R (2003) Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol 56:331-333
12. CYP2C19 [PharmGKB]. Available at: http://pharmgkb.org/gene/PA124. Accessed 10 May 2012
13. Ivandic BT, Schlick P, Staritz P, Kurz K, Katus HA, Giannitsis E (2006) Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 52:383-388
14. Kim KA, Park PW, Hong SJ, Park JY (2008) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236-242
15. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ (2008) Cytochrome P450 2C19 681 G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925-1934
16. Frere C, Cuisset T, Morange PE, Quilici J, Jau LC, Saut N, Faille D, Lambert M, Vague IJ, Bonnet JL, Alessi MC (2008) Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101:1088-1093
17. Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427-2434
18. Tiroch KA, Sibbing D, Koch W, Runge TR, Mehilli J, Schömig A, Kastrati A (2010) Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 160:506-512
19. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, Von Beckerath N, Mehilli J, Schömig A, Schuster T, Kastrati A (2010) Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 8:1685-1693
20. Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJT, Kelder JC, Bouman HJ, Breet NJ, Ten Berg JM, Klungel OH, de Boer A, Deneer VHM (2012) The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 22:169-175
21. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857
22. Yin T, Miyata T (2011) Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 128:307-316
23. Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV (2007) Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154:221-231
24. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM (2010) ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122:537-557